

## Erratum to expanded criteria for active surveillance in prostate cancer: a review of the current data

Cameron Jones<sup>1</sup>, Mina M. Fam<sup>2</sup>, Benjamin J. Davies<sup>2</sup>

<sup>1</sup>University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; <sup>2</sup>Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Correspondence to: Cameron Jones. 1100 Liberty Ave., Suite 507, Pittsburgh, PA 15222, USA. Email: ccj8@pitt.edu.

doi: 10.21037/tau.2018.08.05

View this article at: <http://dx.doi.org/10.21037/tau.2018.08.05>

Erratum to: *Transl Androl Urol* 2018;7:221-7.

*Expanded criteria for active surveillance in prostate cancer: a review of the current data*

The article entitled “Expanded criteria for active surveillance in prostate cancer: a review of the current data” (1) published in Vol 7, No 2 of *Translational Andrology and Urology* included an error in the second sentence of Abstract. In that sentence, “mortality (PCSM)” should be changed to “survival”.

Therefore, the correct sentence should be “Appropriately selected AS patients have a 10-year prostate cancer-specific survival approaching 99%.”

We regret the error and any inconvenience it might have caused.

### References

1. Jones C, Fam MM, Davies BJ. Expanded criteria for active surveillance in prostate cancer: a review of the current data. *Transl Androl Urol* 2018;7:221-7.

**Cite this article as:** Jones C, Fam MM, Davies BJ. Erratum to expanded criteria for active surveillance in prostate cancer: a review of the current data. *Transl Androl Urol* 2018;7(4):764. doi:10.21037/tau.2018.08.05